GlassScriptPhysician profile
Amanda Leigh Bilko
NPI 1699207886
$1,889.48
in general payments reported to CMS, 2019-2025
36 companies · $606 in 2025
The $606 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.91 · 2020: $24.85 · 2021: $20.00 · 2023: $572 · 2024: $632 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,809.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $358.89 | 2024-2025 | |
| Pfizer INC. | $164.16 | 2019-2025 | |
| Abbvie INC. | $135.42 | 2023-2025 | |
| Amgen INC. | $131.87 | 2023 | Kyprolis, Prolia |
| Janssen Biotech, INC. | $124.10 | 2023-2025 | Tecvayli, Talvey, Darzalex |
| Glaxosmithkline, LLC. | $78.87 | 2025 | Blenrep, Ojjaara |
| Celgene Corporation | $78.69 | 2024-2025 | Reblozyl, Opdualag |
| Genzyme Corporation | $77.40 | 2023 | |
| Incyte Corporation | $64.37 | 2023-2025 | Jakafi, Pemazyre, Monjuvi |
| Daiichi Sankyo INC. | $62.78 | 2023-2025 | Injectafer, Datroway |
| Gilead Sciences, INC. | $48.32 | 2024-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $47.84 | 2024 | Lynparza |
| Stemline Therapeutics INC. | $43.22 | 2023-2024 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $40.21 | 2021-2023 | Epkinly, Imbruvica |
| Array Biopharma INC | $38.33 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $23.91 | 2024 | Polivy, Columvi, Lunsumio |
| Beigene USA, INC. | $22.12 | 2024 | Brukinsa |
| Beone Medicines USA, INC. | $22.00 | 2025 | Brukinsa |
| Accord Healthcare, INC. | $21.43 | 2024 | |
| Merck Sharp & Dohme LLC | $21.20 | 2023 | Lynparza, Keytruda |
| Alexion Pharmaceuticals, INC. | $20.53 | 2024 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $20.21 | 2023 | Rezlidhia, Tavalisse |
| Genmab U.S., INC. | $20.18 | 2023 | Epkinly |
| Regeneron Healthcare Solutions, INC. | $20.09 | 2024 | Libtayo |
| Adc Therapeutics America, INC. | $19.37 | 2025 | |
| Acrotech Biopharma INC. | $19.01 | 2023 | Beleodaq |
| Sun Pharmaceutical Industries INC. | $18.48 | 2023 | Yonsa, Odomzo |
| Spectrum Pharmaceuticals INC. | $18.41 | 2023 | Rolvedon |
| Pharmaessentia USA Corporation | $17.97 | 2025 | Besremi |
| Emd Serono, INC. | $16.76 | 2023 | Bavencio |
| Tempus Ai, INC | $16.70 | 2025 | Xt Cdx |
| Seagen INC. | $16.51 | 2023 | Tukysa |
| E.R. Squibb & Sons, L.L.C. | $15.85 | 2025 | Opdivo |
| Sobi, INC | $15.54 | 2024 | |
| Jazz Pharmaceuticals INC. | $14.61 | 2024 | |
| Mirati Therapeutics, INC. | $14.13 | 2024 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Bilko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.